Abstract:The blood coagulation protein factor XI (FXI) consists of a pair of disulfide-linked chains each containing four apple domains and a catalytic domain. The apple 4 domain (A4; F272-E362) mediates non-covalent homodimer formation even when the cysteine involved in an intersubunit disulfide is mutated to serine (C321S). To understand the role of non-covalent interactions stabilizing the FXI dimer, equilibrium unfolding of wild-type A4 and its C321S variant was monitored by circular dichroism, intrinsic tyrosine fluorescence and dynamic light scattering measurements as a function of guanidine hydrochloride concentration. Global analysis of the unimolecular unfolding transition of wild-type A4 revealed a partially unfolded equilibrium intermediate at low to moderate denaturant concentrations. The optically detected equilibrium of C321S A4 also fits best to a three-state model in which the native dimer unfolds via a monomeric intermediate state. Dimer dissociation is characterized by a dissociation constant, K(d), of approximately 90 nM (in terms of monomer), which is in agreement with the dissociation constant measured independently using fluorescence anisotropy. The results imply that FXI folding occurs via a monomeric equilibrium intermediate. This observation sheds light on the effect of certain naturally occurring mutations, such as F283L, which lead to intracellular accumulation of non-native forms of FXI. To investigate the structural and energetic consequences of the F283L mutation, which perturbs a cluster of aromatic side-chains within the core of the A4 monomer, it was introduced into the dissociable dimer, C321S A4. NMR chemical shift analysis confirmed that the mutant can assume a native-like dimeric structure. However, equilibrium unfolding measurements show that the mutation causes a fourfold increase in the K(d) value for dissociation of the native dimer and a 1 kcal/mol stabilization of the monomer, resulting in a highly populated intermediate. Since the F283 side-chain does not directly participate in the dimer interface, we propose that the F283L mutation leads to increased dimer dissociation by stabilizing a monomeric state with altered side-chain packing that is unfavorable for homodimer formation.

Structural Determinants For Heparin Binding In Human Coagulation Factor Xi

Binding between the Integrin αXβ2 (CD11c/CD18) and Heparin

Factor XI Homodimer Structure is Essential for Normal Proteolytic Activation by Factor XIIa, Thrombin, and Factor XIa.

Characterization of the Heparin-Binding Site of the Protein Z-Dependent Protease Inhibitor

Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin.

Dimer dissociation and unfolding mechanism of coagulation factor XI apple 4 domain: spectroscopic and mutational analysis

Surface plasmon resonance analysis to evaluate the importance of heparin sulfate groups' binding with human aFGF and bFGF

Preparation and Structure of A New Coagulation Factor Xi Catalytic Domain for Drug Discovery

Thrombin activation of the factor XI dimer is a multistaged process for each subunit

Helix D Elongation and Allosteric Activation of Antithrombin

Structural Analysis of Heparin-Derived 3-O-sulfated Tetrasaccharides: Antithrombin Binding Site Variants.

Heparin Activation of Protein Z-dependent Protease Inhibitor (ZPI) Allosterically Blocks Protein Z Activation Through an Extended Heparin-Binding Site.

Characterization of Heparin's Conformational Ensemble by Molecular Dynamics Simulations and Nuclear Magnetic Resonance Spectroscopy.

The Disulfide Bond between Cys22 and Cys27 in the Protease Domain Modulate Clotting Activity of Coagulation Factor X.

Discovery of Heparin Mimetic, Potent, and Selective Inhibitors of Human Clotting Factor XIIIa

Experimental proof for the structure of a thrombin-inhibiting heparin molecule

Binding of coagulation factor IXa to procoagulant platelets revisited: Low affinity and interactions with other factors

Hydrolysis of Heparinase Ⅰ to SyntheticHeparin-Pentasaccharide and Effecton Its Anti-factor Xa Activity

Targeting the S2 Subsite Enables the Structure-Based Discovery of Novel Highly Selective Factor XIa Inhibitors.

Heparin Makes Differences: a Molecular Dynamics Simulation Study on the Human Βii-Tryptase Monomer